Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

|Videos|December 13, 2022

Dr. Mirza on pros and cons of virtual interviews for urology residency programs

Author(s)Urology Times staff

Moben Mirza, MD, FACS, Residency Program Director and Professor, Department of Urology, University of Kansas, discusses the advantages and disadvantages of virtual interviews for both urology residency applicants and the programs themselves.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

From hype to practice: Urologists assess AI's real impact

ByHannah Clarke

July 30th 2026

The UroOnc Minute: Optimizing Patient Follow-Up in Urologic Oncology, With Jason Hafron, MD

ByAdam B. Weiner, MD,Jason Hafron, MD

July 24th 2026

University of Florida chief residents discuss mentorship, self-care, and residency success

ByMiranda Eubank, MD,Trisha U. Nguyen, MD,Jordan Matthews-Smith, MD

July 15th 2026

The UroOnc Minute: Making Appointments More Effective, With David Canes, MD

ByAdam B. Weiner, MD,David Canes, MD

July 3rd 2026

Money Matters: How can you plan for your retirement income needs?

ByRonald J. Paprocki, JD, CFP, CHBC

May 29th 2026

Latest CME

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC

Testosterone deficiency: FAQs from the AUA guideline

Individualizing androgen pathway therapy in mCSPC

Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer

Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice